SimpleScreen CRC
Freenome, LLC · Decision date Jul 24, 2026
What did the FDA approve?
FDA records P250029 as an original PMA application. The recorded decision is approval, dated Jul 24, 2026.
FDA approval order statement
The SimpleScreen CRC test is a qualitative, in vitro diagnostic test intended to detect molecular signals associated with colorectal cancer. SimpleScreen CRC utilizes circulating cell-free DNA from plasma of peripheral whole blood collected in the SimpleScreen CRC blood collection kit.SimpleScreen CRC is indicated for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. Patients with a positive result should be followed by colonoscopy. SimpleScreen CRC is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Medical Genetics
- Decision date
- Jul 24, 2026
Regulatory record facts
- Identifier
- P250029
- Regulatory pathway
- Premarket approval application
- Applicant
- Freenome, LLC
- Product code
- PHP
- Decision code
- APPR
- Decision date
- Jul 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, colorectal neoplasia, DNA methylation and hemoglobin detection.
- Applicant
- Freenome, LLC
- Product code
- PHP
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250029 received
Application receipt date recorded by FDA.
P250029 · FDA decision
APPR
P250029/S003 · Related supplement
SimpleScreen CRC
Timeline entries are records held by MedtechLedger for P250029. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250029
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SimpleScreen CRCP250029/S003 | Freenome, LLC | PMA supplement | Oct 27, 2026 | FDA |
Explore the linked device profile
Other records with product code PHP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ShieldP230009/S021 | Guardant Health, Inc. | PMA supplement | Oct 5, 2026 | FDA |
ShieldP230009/S020 | Guardant Health, Inc. | PMA supplement | Sep 16, 2026 | FDA |
ShieldP230009 | Guardant Health, Inc. | PMA approval | Jul 26, 2024 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Freenome, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Bldg. 1, 3300 Marina Blvd., Brisbane, CA, 94005
Sources and methodology
- Original FDA record: P250029
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


